College of American Pathologists Protocol for the Reporting of Ductal Carcinoma In Situ

ArticleinArchives of pathology & laboratory medicine 133(1):13-4 · February 2009with5 Reads
Impact Factor: 2.84 · DOI: 10.1043/1543-2165-133.1.13 · Source: PubMed
    • "These two cases were high grade DCIS and no invasive disease was identified. The size of DCIS was not analyzed in this study as precise size measurement is controversial and difficult to assess in DCIS [16]. In addition to DCIS, invasive disease was identified on histologic examination in 30 (21%) of the patients. "
    [Show abstract] [Hide abstract] ABSTRACT: Biologic markers that predict development of invasive breast cancer (IBC) in patients diagnosed with ductal carcinoma in situ (DCIS) are needed to improve personalized therapy. In this study, we examined the incidence of early IBC in DCIS subgroups defined by immunophenotype. Clinical and histologic materials of 143 patients with radiographically suggesting DCIS without obvious evidence of IBC were reviewed. All patients underwent initial biopsy followed by short-term subsequent resection. The presence of IBC, histopathologic features of DCIS and IBC, when present, and their estrogen receptor (ER), progesterone receptor (PR), and HER2 phenotypes were evaluated. Early IBC was identified on initial biopsy in 6 (4%) and subsequent resection in 24 (17%) patients. HER2 positivity in DCIS was the dominant factor associated with IBC. There was also a significant association between ER/PR/HER2+ DCIS and the presence of IBC. The ER/PR/HER2+ DCIS appeared to be the most unstable precursor, because of the highest invasion rate and frequent association with a discordant phenotype. HER2 positivity and ER/PR/HER2 phenotype may be used to identify DCIS patients at higher risk of harboring or potentially developing IBC. Strategies targeting HER2 in DCIS may be of potential benefit in preventing IBC in patients with DCIS.
    Full-text · Article · Oct 2011 · Journal of Surgical Oncology
    0Comments 12Citations
    • "Given that DCIS is a heterogeneous disease, the onesize-fits-all approach to treatment seems inappropriate. As tumor characteristics are routinely evaluated by the pathologist, this information could provide valid predictors for recurrence and could optimize treatment decisions [2]. The association between these factors and patient outcomes has been reviewed before [3], but the research is somewhat outdated. "
    [Show abstract] [Hide abstract] ABSTRACT: While ductal carcinoma in situ (DCIS) is seldom life threatening, the management of DCIS remains a dilemma for patients and their physicians. Aggressive treatment reduces the risk of ipsilateral breast tumor recurrence (IBTR), but has never been proven to improve survival. There is interest in identifying the prognostic factors for determining low-risk DCIS patients, but a comprehensive review of high-quality evidence on tumor characteristics in predicting local recurrence has never been carried out. We examined the following tumor characteristics: biomarkers, comedonecrosis, focality, surgical margin, method of detection, tumor grade, and tumor size. For this systematic review we restricted the analyses to the results of subgroup analyses from randomized controlled trials (RCTs) and multivariate analyses from RCTs and observational studies. We identified 44 eligible articles. The pooled random-effects risk estimates for IBTR are comedonecrosis 1.71(95% CI, 1.36-2.16), focality 1.95(95% CI, 1.59-2.40), margin 2.25(95% CI, 1.77-2.86), method of detection 1.35(95% CI, 1.12-1.62), tumor grade 1.81(95% CI, 1.53-2.13), and tumor size 1.63(95% CI, 1.30-2.06). Limited evidence indicated that women whose DCIS is ER-negative, PR-negative, or HER2/neu receptor positive have an IBTR higher than those whose DCIS is ER-positive, PR-positive, and HER2/neu receptor negative. A variety of tumor characteristics are significant predictors for IBTR. These results are important for both clinicians and patients to interpret the risk of local recurrence and to decide on a course of treatment.
    Full-text · Article · Feb 2011 · Breast Cancer Research and Treatment
    0Comments 59Citations
  • No preview · Article · Oct 2009 · Archives of pathology & laboratory medicine
    0Comments 1Citation
Show more